Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25446932 | 1.00 | GAA (0.34) | GAASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL25446933 | 1.00 | GAA (0.34) | GAASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL26365812 | 0.89 | MEN1 (0.33) | GAASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL26444239 | 0.86 | GAA (0.33) | GAASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL15779865 | 0.75 | — | — | |
| SCHEMBL12179302 | 0.71 | — | — | |
| SCHEMBL23660609 | 0.70 | PIK3CD (0.35) | GAASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL23660610 | 0.70 | PIK3CD (0.35) | GAASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL14733933 | 0.70 | PIK3CD (0.35) | GAASMN1; SMN2MEN1ALDH1A1MAPT | |
| SCHEMBL26785271 | 0.70 | DRD2 (0.36) | GAASMN1; SMN2MEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230147833-A1 | OPTICALLY PURE OXASPIRO-SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| US-20230147833-A1 | OPTICALLY PURE OXASPIRO-SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2021143803-A1 | OPTICALLY PURE OXASPIRO-SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 上海海雁医药科技有限公司 | 2021-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230147833-A1 | OPTICALLY PURE OXASPIRO-SUBSTITUTED PYRROLOPYRAZOLE DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | WEE1, CYP51A1, CYP4F11 | GAA 1206/4885SMN1; SMN2 4162/4885MEN1 2271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.